Dallas Renal Group

Dallas, Texas 75237

5 studies enrolling now · 12 studies all time

What they study most

Anemia of Chronic Kidney Disease, Anemia, Iron Deficiency, Arteriovenous Fistula, Chronic Kidney Disease, Difficult to Control Hypertension, Glomerular Disease, Glomerulonephritis, Glomerulonephritis, IGA, Glomerulopathy, Hyperphosphatemia, IgA Nephropathy, Immunoglobulin A Nephropathy

Studies at this site

• A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy — Recruiting now
• Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. — Recruiting now
• Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy — Recruiting now
• To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension — Recruiting now
• Behavioral AI to Predict and Increase Peritoneal Dialysis Uptake — Recruiting now
• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy — Running, not enrolling
• Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis — Completed
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — Running, not enrolling
• Vafseo Outcomes In-Center Experience — Running, not enrolling
• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients — Completed
• Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft — Completed
• Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants — Completed